Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide
US10981973B2 · kind B2 · utility
0Cited by
27References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2019 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Apr 24, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.